Syncom Healthcare Peer Comparison
NSE: SYNCOM | BSE: 533157
₹4.20
As on 28-Jun-2021IST
Market cap
₹16 Cr
Revenue (TTM)
₹5 Cr
P/E Ratio
--
P/B Ratio
-1
Div. Yield
0 %
| Syncom Healthcare | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
16 | 31,863 | 30,485 | 28,611 | 27,284 |
Revenue (₹ Cr) |
5 | 3,564 | 1,936 | 9,205 | 1,462 |
Net Profit (₹ Cr) |
-6.07 | 414.00 | 288.22 | -371.81 | 387.35 |
Net Margin (%) |
-107.88 | 11.23 | 14.79 | -3.93 | 26.01 |
RoE (%) |
-- | 8.38 | 29.77 | -3.85 | 25.18 |
Price to Earnings |
-- | 77.90 | 105.77 | -- | 70.64 |
Price-To-Book |
-0.95 | 6.33 | 22.71 | 3.57 | 15.78 |
Income Statement (₹ Cr)
| Syncom Healthcare | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4.87 | 2,798.00 | 853.89 | 8,171.16 | 717.47 |
|
Total Income
|
5.63 | 2,881.00 | 872.39 | 8,372.30 | 724.97 |
|
Total Expenditure
|
8.05 | 2,759.00 | 699.30 | 7,000.65 | 588.98 |
|
EBITDA
|
-3.18 | 39.00 | 154.59 | 1,170.51 | 128.49 |
|
Depreciation
|
1.93 | 223.00 | 38.97 | 740.57 | 16.06 |
|
EBIT
|
-5.10 | -184.00 | 115.62 | 429.94 | 112.43 |
|
Interest
|
1.73 | 305.00 | 31.26 | 448.49 | 5.94 |
|
Other Income
|
0.76 | 83.00 | 18.50 | 201.14 | 7.49 |
|
Exceptional Items
|
-- | -14.00 | -- | -62.79 | -32.08 |
|
Profit before Tax
|
-6.07 | -420.00 | 102.86 | 179.29 | 81.90 |
|
Provision for Tax
|
-- | 52.00 | 11.85 | 161.47 | 33.19 |
|
Profit after Tax
|
-6.07 | -472.00 | 91.01 | 17.82 | 48.71 |
Liabilities (₹ Cr)
| Syncom Healthcare | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-9.30 | 3,359.00 | 385.00 | 7,911.37 | 674.00 |
|
Minority Interest
|
-- | 303.00 | -- | -- | 8.76 |
|
Non-Current Liabilities
|
5.31 | 617.00 | 151.06 | 2,644.64 | 127.98 |
|
Current Liabilities
|
23.43 | 2,791.00 | 572.50 | 4,369.30 | 285.17 |
|
Total Liabilities
|
19.44 | 7,614.00 | 1,109.49 | 15,082.63 | 1,095.90 |
Assets (₹ Cr)
| Syncom Healthcare | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
12.97 | 4,886.00 | 345.40 | 9,460.84 | 602.60 |
|
Current Assets
|
6.47 | 2,073.00 | 763.17 | 5,464.47 | 493.30 |
|
Total Assets
|
19.44 | 7,614.00 | 1,109.49 | 15,082.63 | 1,095.90 |
|
Total Debt*
|
22.60 | 2,112.00 | 396.41 | 4,558.86 | 216.65 |
|
Net Current Assets
|
-16.96 | -718.00 | 190.67 | 1,095.17 | 208.13 |
|
Contingent Liabilities
|
-- | 882.46 | 10.24 | 61.43 | 2.07 |
Cashflow (₹ Cr)
| Syncom Healthcare | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-1.10 | 219.00 | 21.01 | 1,004.54 | 125.17 |
|
Cash Flow from Investing Activities
|
-0.96 | -137.00 | -68.51 | -434.01 | -365.39 |
|
Cash from Financing Activities
|
1.67 | 334.00 | 43.55 | -422.36 | 239.36 |
|
Net Cash Inflow / Outflow
|
-0.39 | 416.00 | -3.95 | 148.17 | -0.86 |
Ratios
Profitability Ratios
| Syncom Healthcare | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-29.65 | -2.15 | 19.36 | 5.07 | 11.81 |
|
ROE (%)
|
0.00 | -14.12 | 28.75 | 0.24 | 7.70 |
|
ROA (%)
|
-30.00 | -6.67 | 9.80 | 0.12 | 5.23 |
|
EBIT Margin (%)
|
-49.59 | 4.36 | 20.27 | 16.79 | 18.95 |
|
Net Margin (%)
|
-107.88 | -16.38 | 10.43 | 0.21 | 6.72 |
|
Cash Profit Margin (%)
|
-85.20 | -6.91 | 15.22 | 8.05 | 9.03 |
Growth Ratios
| Syncom Healthcare | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
61.46 | 5.55 | 116.99 | 15.39 | 16.33 |
|
EBIT Growth (%)
|
-22.83 | -45.29 | 293.63 | 60.74 | 7.13 |
|
Net Profit Growth (%)
|
-12.75 | 23.99 | 638.92 | 109.56 | -41.52 |
|
EPS Growth (%)
|
-12.75 | 22.55 | 638.92 | 108.83 | -49.26 |
|
Book Value Growth (%)
|
-188.43 | 0.24 | 32.89 | 16.39 | 13.09 |
Valuation Ratios
| Syncom Healthcare | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 0.00 | 0.00 | 956.95 | 47.18 |
|
Price / Book Value
|
0.00 | 2.69 | 0.00 | 2.16 | 6.01 |
|
Dividend Yield (%)
|
-- | 0.00 | -- | 0.09 | 0.27 |
|
EV/EBITDA
|
-10.60 | 86.64 | 2.04 | 15.40 | 30.88 |
|
Market Cap (₹ Cr)
|
0.00 | 8,986.62 | 0.00 | 17,053.21 | 4,036.01 |
Solvency Ratios
| Syncom Healthcare | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-2.43 | 0.63 | 1.10 | 0.58 | 0.32 |
|
Short term debt to equity ratio
|
-1.91 | 0.25 | 0.69 | 0.15 | 0.11 |
|
Current Ratio
|
0.28 | 0.74 | 1.33 | 1.25 | 1.73 |
|
Quick Ratio
|
0.24 | 0.51 | 0.81 | 0.75 | 1.18 |
|
Interest Coverage
|
-2.50 | -0.38 | 4.29 | 1.40 | 14.79 |
Operating Efficiency Ratios
| Syncom Healthcare | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
40.82 | 22.09 | 35.31 | 26.12 | 28.76 |
|
Asset Turnover
|
0.24 | 0.51 | 0.92 | 0.64 | 0.77 |
|
Receivable days
|
137.93 | 71.63 | 112.52 | 76.20 | 111.06 |
|
Inventory Days
|
85.19 | 65.71 | 99.96 | 74.72 | 70.18 |
|
Payable days
|
266.53 | 255.81 | 194.81 | 168.73 | 122.64 |
|
Cash Conversion Cycle
|
-43.41 | -118.47 | 17.67 | -17.80 | 58.60 |